<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15004">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911545</url>
  </required_header>
  <id_info>
    <org_study_id>FinCV3</org_study_id>
    <nct_id>NCT02911545</nct_id>
  </id_info>
  <brief_title>Non-vitamin K Oral Anticoagulants in Cardioversion</brief_title>
  <acronym>FinCV3</acronym>
  <official_title>Non-vitamin K Oral Anticoagulants in Cardioversion of Atrial Fibrillation. FinCV3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective
      alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There
      are yet limited real life data on outcomes following elective cardioversion in AF patients
      treated with NOACs. The aim of this study is to investigate the complications and the use of
      NOACs in AF patients undergoing cardioversion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and predictors of thromboembolic complications</measure>
    <time_frame>31 days after cardioversion of persistent AF</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and predictors of bleeding</measure>
    <time_frame>31 days after cardioversion of persistent AF</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of recurrence of AF</measure>
    <time_frame>31 days after cardioversion of persistent AF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic complications of cardioversion</measure>
    <time_frame>31 days after cardioversion of persistent AF</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        AF patients undergoing cardioversion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AF patients undergoing cardioversion

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Lehto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 21, 2016</lastchanged_date>
  <firstreceived_date>September 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Mika Lehto</investigator_full_name>
    <investigator_title>MD, PhD, cardiologist</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
